The Food and Drug Administration's action follows its advisory panel's unanimous recommendation for the shots from Moderna and Pfizer. That means US kids under 5, roughly 18 million youngsters, are eligible for the shots
While the US government is purchasing more Paxlovid, patients, scientists and even federal agencies are uncertain about its effectiveness as in several cases people have complained of experiencing a second round of symptoms in what is being called as “rebound illness” or 'Paxlovid rebound'
WHO's recommendation was based on the findings of two trials involving almost 3,100 patients which showed that Paxlovid reduced the risk of hospital admission by 85 percent
India's 'warm vaccine' candidate effective against Delta, Omicron COVID-19 variants in mice, says study
The latest study, published recently in the journal Viruses, assessed vaccinated mice sera (blood samples) for efficacy against key coronavirus variants, including Delta and Omicron.
The Food and Drug Administration said it cleared the Eli Lilly drug for adults and adolescent patients with mild-to-moderate cases of COVID-19 that also works against the emerging BA.2 mutation of Omicron
The FDA's decision could come within the month, but that isn't the only hurdle, the Centers for Disease Control and Prevention also has to sign off for steps to be initiated
This comes a day after rivals Pfizer and BioNTech said they had begun enrollment for a clinical trial for an Omicron-specific vaccine
The announcement comes after Unilever failed with a $68-billion takeover bid for the consumer health care unit owned by pharmaceutical groups GlaxoSmithKline and Pfizer
Boosters already are recommended for everyone 16 and older, and federal regulators on Monday decided they’re also warranted for 12- to 15-year-olds once enough time has passed since their last dose
Israel was among the first countries to roll out Pfizer's coronavirus vaccine a year ago and began rolling out boosters last summer
The study, published in the journal Nature on Thursday, also highlights the need for new vaccines and treatments that anticipate how the SARS-CoV-2 virus may soon evolve.
The FDA has not authorized Merck's pill for people under 18 because it may affect bone and cartilage growth.
Separate laboratory testing shows the drug retains its potency against the omicron variant, the company announced, as many experts had predicted
Preliminary results from a small study in South Africa suggested there was up to a 40-fold drop in the ability of the antibodies from the Pfizer-BioNTech vaccine to neutralise Omicron
Compared to 2019, when there was little urgency or chatter about vaccines, Merriam-Webster logged an increase of 1,048 percent in lookups this year
Health officials said the fact that the deal was struck even before Pfizer's pill has been authorized anywhere, could help to end the pandemic quicker
COVID-19 vaccines have been successful in preventing severe disease, but the deployment of these antivirals will still be significant given that vaccines aren’t protective 100 percent of the time
Currently all COVID-19 treatments used in the US require an IV or injection
The FDA assessed the safety of the kid-size doses in 3,100 vaccinated youngsters and has said that kids between 5 to 11 years will get just a third of the dose given to teens and adults.
The decision marks the first opportunity for Americans under 12 to get the powerful protection of any COVID-19 vaccine